| Literature DB >> 32410790 |
Osman Nuri Dilek1, Feyyaz Güngör1, Turan Acar1, Arif Atay1, Şebnem Karasu2, Halis Bağ1, Fatma Hüsniye Dilek3.
Abstract
Hepaticojejunostomy is a challenging and complex procedure to be done with confidence in conditions that contain a large number of segmental bile ducts. Portoenterostomy can be defined as the joining of multiple bile ducts into a single cavity using segmenter bile duct ends, stents, and surrounding connective tissues. During surgery, in cases with advanced stage biliary tract tumors that cannot be performed hepatectomy, after aggressive dissections to provide a negative surgical margin, a large number of segmental bile ducts can be revealed and needs to ensure the continuity of bile flow. Here, our clinical series of portoenterostomy (PE) in which we applied in patients who had aggressive hilar dissection and resection for hilar cholangiocarcinomas and biliary tract tumors were discussed. The study included 15 patients who underwent PE for biliary tract tumors and hilar cholangiocarcinomas between 2015 and 2019. Six of the patients had a tumor-negative surgical margin, with a mean follow-up of 14.4 months (range 2 to 28 months). Nine of the patients had a tumor-positive surgical margin, with a mean follow-up of 7.7 months (range 2 to 17 months). Portoenterostomy instead of hepaticojejunostomy in small and multiple biliary radicles and bile duct cancers has been successfully performed in 15 patients of bile duct cancer and Klatskin tumor. In the presence of active inflammation, fibrosis, major bile duct trauma, and thin bile duct radicles, this method, which is described in detail, provides an excellent salvage surgical procedure with less morbidity. © Association of Surgeons of India 2020.Entities:
Keywords: Biliary tract tumor; Klatskin tumor; Portoenterostomy; Treatment
Year: 2020 PMID: 32410790 PMCID: PMC7222060 DOI: 10.1007/s12262-020-02259-y
Source DB: PubMed Journal: Indian J Surg ISSN: 0973-9793 Impact factor: 0.656
Fig. 1a The specimen of hilar structures after aggressive hilar resection and multiple bile duct ends (stents). b Bile ducts (stents-arrow heads)
Fig. 2The portoenterostomy stitch technique. Corner sutures (1, 3), posterior wall sutures (2), and anterior wall sutures between the jejunum and thin bile ducts (4)
Fig. 3Cholangiography taken postoperative 15th day with the PTC catheter shows the anastomotic patency
Demographic data of the patients
| Pt | M/F age | History/diagnosis/pathology/etiology | PTC/ERCP/Labs | Procedure | Results/survey |
|---|---|---|---|---|---|
| 1. | F 76 | Klatskin tumor (type 3) Adenocarcinoma-G3 | Bil.:21.60, Ca-19.9:355 PTC stenting | EHBDR + PE (2015) | Relaparotomy on 2nd day excitus (hemorrhagic shock) |
| 2. | M 59 | COPD, meningitis sequelae, Klatskin tumor? (type 3) bile duct ulcer, fibrosis, cholestasis, benign stricture, IgG4+, SM- | Bil.: 20.07,Ca-19.9:197 ERCP/PTC stenting (2017) | EHBDR + PE (2017) | Evisceration-primary suture (COPD, pneumonia), excitus, 2 m |
| 3. | M 58 | Klatskin tumor (type 2–3) Adenocarcinoma – G1 SM- | Bil.:20.48, Ca-19.9:37 PTC stenting | WP + + EHBDR + PE (2017) + CT | Stabile + liver metastasis + abscess + PTC stenting excitus, 28 m |
| 4. | M 69 | Klatskin tumor (type 2) Adenocarcinoma – G1 (neuroendocrine tumor), SM- | Bil.:15.99, Ca-19.9:Normal ERCP stenting | EHBDR + PE (2017) + CT + RT | Liver metastasis (recurrence?), excitus, 11 m |
| 5. | F 76 | Crohn’s disease (2012), Klatskin tumor (type 3) Adenocarcinoma – G2, SM- | Bil.: 24.35,Ca-19-9:112 PTC right and left stenting | EHBDR + PE (2018) + RT | Stabile, 19 m |
| 6. | M 74 | Klatskin tumor (type 3) Adenocarcinoma – G3, SM- | Bil.: 6.17,Ca-19.9:39 ERCP stenting (2019) | EHBDR+ PE (2019) + CT + RT | Bile leakage (7 days), liver abscess (drainage), stabile, 12 m |
| 7. | M 43 | Klatskin tumor (type 3) Invasion of portal vein conf., Adenocarcinoma – G2, SM+ | Bil.:17.44,Ca-19.9:129 PTC stenting | EHBDR + PE (2015) + RT | Liver metastasis, recurrence? excitus, 17 m |
| 8. | M 66 | Klatskin tumor (type 2) Adenocarcinoma – G2, SM+ | Bil.:24.11,Ca-19.9:93 ERCP stenting | EHBDR+ PE (2016) | Excitus (etiology?) 9 m |
| 9. | F 78 | COPD + Klatskin tumor (type 3) Adenocarcinoma – G1, SM+ | Bil.:12.46,Ca-19.9:N PTC stenting | EHBDR + PE (2017) | Pneumonia, excitus, 2 m |
| 10. | F 61 | Gallbladder carcinoma + EHBD invasion Adenocarcinoma – G3, SM+ | Bil.:16.26, Ca-19.9:200 PTC stenting | Liver S4B and 5 resection + EHBDR + PE (2018) + RT | Stabile, malign hypercalcemia + liver metastasis Excitus, 10 m |
| 11. | M 68 | Klatskin tumor (type 2) Tumor thrombus Adenocarcinoma – G3, SM+ | Bil.:25+, Ca-19-9:52 PTC, metal stent (ingrowth) (2018), and 2nd stenting | EHBDR + PE (2019) (refused CT and RT) | Recurrence and metastasis excitus, 5 m |
| 12. | M 74 | Klatskin tumor, (type 3) Adenocarcinoma – G3, SM+ | Bil: 11.9, Ca-19.9: 41 ERCP + stenting | EHBDR + PE (2019) + CT + RT | Excitus (etiology?) 9 m |
| 13. | M 70 | Gallbladder carcinoma + EHBD invasion + distal bile duct invasion (frosen +) Adenocarcinoma – G2, SM+ | Bil: 2.65, Ca-19.9: 48 Distal surgical margin tumor positivity | Liver S4B + 5 resection + EHBDR + WP + PE (2019) + CT + RT | Stabile + CT + RT multiple lung metastasis + cholangitis, excitus 3 m |
| 14. | M 55 | Klatskin tumor (type 4) Adenocarcinoma – G3, SM+ | Bil: 18.4, CA-19.9: 400 Frosen; right and left hepatic bile duct margins were tumor positive | Right hepatectomy + caudate lobe resection + EHBDR + PE (2019) CT + RT | Stabile, 9 m |
| 15. | M 54 | EHBD tumor Adenocarcinoma – G2, SM+ | Bil: 24.75, Ca19.9: N Proximal and distal surgical margins tumor positivity | EHBDR + PE + WP (2nd Operation) (2019) + CT + RT | Stabile, 6 m |
COPD chronic obstructive pulmonary disease, CT Chemothreapy, G tumor grade, EHBDR extrahepatic bile duct resection, m month, PTC percutan transhepatic cholangiography, RT radiotherapy, SM surgical margin, WP Whipple procedure
Fig. 4Surgery (a) picture shows that the inner stent (2, blue) was placed with PTC due to the tumor ingrowth of the metal stent (1). Specimen (b) shows gallbladder and main bile duct and hepatolithiasis (3). (R, right hepatic bile ducts; L, left hepatic bile ducts)